What’s Next In Vaccines (Malaria, Diabetes, Alzheimer’s, Allergies and 30 Other Targets in the 2012-2021 Vaccine Pipeline)

2012-07-09
Published : Jul-2012

Vaccines are one of the most dynamic parts of the pharmaceutical business today but future growth will depend on a considerable amount of potential vaccines in the pipeline.This Kalorama Information report What’s Next in Vaccines? examines and estimates the market for vaccines that have yet to be launched.    What diseases may see a prophylactics vaccine option in the coming years? Which vaccines will have the most successful business model? Who are the major companies in this market, and possible new entrants? What can current vaccine success stories tell us about the future of the vaccine market?  The following target areas are covered in the report:

  • Acne
  • Addiction
  • Allergy
  • Alzheimer’s Disease
  • Anthrax
  • Asthma
  • Campylobacter Infection
  • Chlamydia
  • Croup
  • Cytomegalovirus (CMV)
  • Dengue Fever
  • Diabetes
  • Ebola
  • Epstein-Barr Virus
  • Enterotoxigenic Escherichia coli (ETEC)
  • Heart Attack
  • Helicobacter Pylori
  • Hepatitis
  • Herpesvirus
  • Hookworm
  • Hypertension
  • HIV/AIDS
  • Leishmaniasis
  • Malaria
  • MRSA Infection
  • Multiple Sclerosis
  • Obesity
  • Parainfluenza Virus Type 3
  • Parkinson’s Disease
  • Plague
  • Ross River Virus
  • Shigellosis
  • Stroke
  • Tuberculosis
  • West Nile Virus
Report Details:
Published: June 2012
No. of Pages: 215
Price: Single User License: US$ 3995         Corporate User License: US$ 7990

For each of these areas the report provides Mortality, Severity and Treatment Availability ratings. For marketers and industry watchers a knowledge of all of the potential vaccines will be important to understand how pharma is seeking to renew bottom line with aggressive prophylactic strategies, and who the winners and losers in the near future may be. Kalorama Information has looked at the vaccine market three times in as many years for Kalorama Information, and in this report applies a knowledge of what companies have done in the past to potential efforts.

There are a number of trends that will impact the industry that market watchers will want to know about, and Kalorama Information has covered these trends; including: New Vaccine Technologies, DNA Vaccination, Recent Project Terminations, Innovative Delivery Systems, Edible Vaccines, Vaccine Patches, Funding Shortfalls. The report also discusses vaccine manufacturing methods and the approval process. In addition, the report focuses on the emerging vaccine activities of the following companies

  • Affiris
  • Alk-Abello A/S
  • Allergy Therapeutics
  • AstraZeneca
  • Bavarian Nordic A/S
  • Baxter Healthcare
  • Crucell
  • Cytos Biotechnology
  • GlaxoSmithKline
  • Hawaii Biotech
  • Merck & Co. Inc
  • Mymetics
  • Nabi Biopharmaceuticals
  • Novartis
  • Opexa Therapeutics
  • Sanofi Pasteur

This report provides forecasted revenues for products in development out to 2021. The report does not does not cover indication expansions of existing vaccine products, nor does it cover vaccines for which products currently exist and are widely available, but may need improvement. Development of vaccines that incorporate new production methods (such as the migration of chicken eggs to mammal, yeast or other cells) is also excluded. Cancer vaccines are excluded as Kalorama has an entire report on this topic.

Sales estimates for each market segment represent global revenues and are expressed in current dollars. Information for this report was gathered from a wide variety of published sources including company reports and filings, government documents, legal filings, trade journals, newspapers and business press, analysts’ reports and other sources

Table Of contents

CHAPTER ONE: EXECUTIVE SUMMARY
Emerging Vaccines
Scope and Methodology
Overview
Emerging Vaccines and Forecasts
The Global Market for Emerging Vaccines

CHAPTER TWO: INTRODUCTION TO VACCINES
A Brief History: The Development of Vaccines
The Immune Response
Mechanism of Action
Types of Vaccines
Attenuated (Weakened) Live Viruses
Killed (Inactivated) Viruses
Toxoid Vaccines
Genetically Engineered/Modified Vaccines
Bacteria-Based Vaccines
Vaccine Approval Process
Refusal to Immunize
Expanding Vaccine Availability
Other Trends Driving the Vaccines Market

CHAPTER THREE: EMERGING VACCINES
Introduction
Emerging Vaccines by Disease Area
Acne
Addiction
Allergy
Alzheimer’s Disease
Anthrax
Asthma
Campylobacter Infection
Chlamydia
Croup
Cytomegalovirus (CMV)
Dengue Fever
Diabetes
Ebola
Epstein-Barr Virus
Enterotoxigenic Escherichia coli (ETEC
Heart Attack
Helicobacter Pylori
Hepatitis
Herpesvirus
Hookworm
Hypertension
HIV/AIDS
Leishmaniasis
Malaria
MRSA Infection
Multiple Sclerosis
Obesity
Parainfluenza Virus Type 3
Parkinson’s Disease
Plague
Ross River Virus
Shigellosis
Stroke
Tuberculosis
West Nile Virus

CHAPTER FOUR: EMERGING VACCINES MARKET FORECAST
the Global Market for Emerging Vaccines
Emerging Vaccines Market Segment Forecasts
Acne
Addiction
Allergies
Alzheimer’s Disease
Anthrax
Asthma
Campylobacter Infection
Celiac Disease
Chlamydia
Croup
Diabetes
Ebola
EBV Infection
ETEC Infection
Heart Attack
H. Pylori Infection
Hepatitis C and E
Herpesvirus Infection
Hookworm
Hypertension
HIV/AIDS
Leishmaniasis
Malaria
MRSA Infection
Multiple Sclerosis
Obesity
PIV-3 Infection
Parkinson’s Disease
Plague
RSV Infection
Ross River Virus Infection
Shigellosis
Stroke
Tuberculosis
West Nile Virus

CHAPTER FIVE: ISSUES AND TRENDS
New Vaccine Delivery System
Edible Vaccines
Mucosal Delivery
Intranasal Delivery
Vaccine Patches
Funding Shortfalls
Project Terminations

CHAPTER SIX: COMPANY PROFILES
Affiris
History and Lines of Business
Emerging Vaccine Activities
Financial Information
Alk-Abello A/S
History and Lines of Business
Emerging Vaccine Activities
Financial Information
Allergy Therapeutics
History and Lines of Business
Emerging Vaccine Activities
Financial Information
AstraZeneca
History and Lines of Business
Emerging Vaccine Products
Financial Information
Bavarian Nordic A/S
History and Lines of Business
Emerging Vaccine Activities
Financial Information
Baxter Healthcare
History and Lines of Business
Emerging Vaccine Activities
Financial Information
Crucell
History and Lines of Business
Emerging Vaccine Activities
Financial Information
Cytos Biotechnology
History and Lines of Business
Emerging Vaccine Activities
Financial
GlaxoSmithKline
History and Lines of Business
Emerging Vaccine Activities
Financial Information
Hawaii Biotech
History and Lines of Business
Emerging Vaccine Products
Financial Information
Merck & Co. Inc
History and Lines of Business
Emerging Vaccine Activities
Financial Information
Mymetics
History and Lines of Business
Emerging Vaccine Products
Financial Information
Nabi Biopharmaceuticals
History and Lines of Business
Emerging Vaccine Activities
Financial Information
Novartis
History and Lines of Business
Emerging Vaccine Activities
Financial Information
Opexa Therapeutics
History and Lines of Business
Emerging Vaccine Activities
Financial Information
Sanofi Pasteur
History and Lines of Business
Emerging Vaccine Activities
Financial Information
APPENDIX: COMPANY DIRECTORY

List Of Exhibits

CHAPTER ONE: EXECUTIVE SUMMARY
Table 1-1: Status of Emerging Vaccines by Disease
CHAPTER TWO: INTRODUCTION TO VACCINES
Table 2-1: Impact of Vaccines in the 20th Century Annual Morbidity in the 20th Century vs 2011
Table 2-2: Vaccine-Preventable Diseases, December 2011
Figure 2-1: Attenuated Virus Production
Table 2-3: VAERS Table of Reportable Events Following Vaccination
CHAPTER THREE: EMERGING VACCINES
Figure 3-1: Global Prevalence of Conditions Addressed by Emerging Vaccines, 2012
Figure 3-2: Comparative Mortality, Symptom Severity and Treatment Availability for Conditions Addressed by Emerging Vaccines
Table 3-1: Emerging Vaccines by Disease and Stage of Testing
Figure 3-3: Comparative Severity Ranking of Acne
Figure 3-4: Comparative Severity Ranking of Addiction
Figure 3-5: Comparative Severity Ranking of Allergy
Figure 3-6: Comparative Severity Ranking of Alzheimer’s Disease
Figure 3-7: Comparative Severity Ranking of Anthrax
Figure 3-8: Comparative Severity Ranking of Asthma
Figure 3-9: Comparative Severity Ranking of Campylobacter Infection
Figure 3-10: Comparative Severity Ranking of Celiac Disease
Figure 3-11: Comparative Severity Ranking of Chlamydia
Figure 3-12: Comparative Severity Ranking of Croup
Figure 3-13: Comparative Severity Ranking of Cytomegalovirus
Figure 3-14: Comparative Severity Ranking of Dengue Fever
Figure 3-15: Comparative Severity Ranking of Diabetes
Figure 3-16: Comparative Severity Ranking of Ebola
Figure 3-17: Comparative Severity Ranking of EBV
Figure 3-18: Comparative Severity Ranking of ETEC
Figure 3-19: Comparative Severity Ranking of Heart Attack
Figure 3-20: Comparative Severity Ranking of H. Pylori Infection
Figure 3-21: Comparative Severity Ranking of Hepatitis C and E
Figure 3-22: Comparative Severity Ranking of Herpesvirus Infection
Figure 3-23: Comparative Severity Ranking of Hookworm
Figure 3-24Comparative Severity Ranking of Hypertension
Figure 3-25: Comparative Severity Ranking of HIV/AIDS
Figure 3-26: Comparative Severity Ranking of Leishmaniasis
Figure 3-27: Comparative Severity Ranking of Malaria
Figure 3-28: Comparative Severity Ranking of MRSA Infection
Figure 3-29: Comparative Severity Ranking of Multiple Sclerosis
Figure 3-30: Comparative Severity Ranking of Obesity
Figure 3-31: Comparative Severity Ranking of PIV-3 Infection
Figure 3-32: Comparative Severity Ranking of Parkinson’s Disease
Figure 3-33: Comparative Severity Ranking of Plague
Figure 3-34: Comparative Severity Ranking of RSV Infection
Figure 3-35: Comparative Severity Ranking of Ross River Virus Infection
Figure 3-36: Comparative Severity Ranking of Shigellosis
Figure 3-37: Comparative Severity Ranking of Stroke
Figure 3-38: Comparative Severity Ranking of Tuberculosis
Figure 3-39: Comparative Severity Ranking of West Nile Virus Infection
CHAPTER FOUR: MARKET ANALYSIS
Table 4-1:World Market for Emerging Vaccines by Type, 2011
Table 4-2: World Market for Emerging Vaccines by Type, 2011-2021
Table 4-3: World Acne Vaccine Market 2011-2021
Table 4-4: World Addiction Vaccine Market 2011-2021
Table 4-5: World Allergy Vaccine Market 2011-2021
Table 4-6: World Alzheimer’s Disease Vaccine Market 2011-2021
Table 4-7: World Anthrax Vaccine Market 2011-2021
Table 4-8: World Asthma Vaccine Market 2011-2021
Table 4-9: World Campylobacter Vaccine Market 2011-2021
Table 4-10: World Celiac Disease Vaccine Market 2011-2021
Table 4-11: World Chlamydia Vaccine Market 2011-2021
Table 4-12: World Croup Vaccine Market 2011-2021
Table 4-13: World Cytomegalovirus Vaccine Market 2011-2021
Table 4-14: World Dengue Fever Vaccine Market 2011-2021
Table 4-15: World Diabetes Vaccine Market 2011-2021
Table 4-16: World Ebola Vaccine Market 2011-2021
Table 4-17: World EBV Vaccine Market 2011-2021
Table 4-18: World ETEC Vaccine Market 2011-2021
Table 4-19: World Heart Attack Vaccine Market 2011-2021
Table 4-20: World H. Pylori Vaccine Market 2011-2021
Table 4-21: World Hepatitis C & E Vaccine Market 2011-2021
Table 4-22: World Herpesvirus Vaccine Market 2011-2021
Table 4-23: World Hookworm Vaccine Market 2011-2021
Table 4-24: World Hypertension Vaccine Market 2011-2021
Table 4-25: World HIV/AIDS Vaccine Market 2011-2021
Table 4-26: World Leishmaniasis Vaccine Market 2011-2021
Table 4-27: World Malaria Vaccine Market 2011-2021
Table 4-28: World MRSA Vaccine Market 2011-2021
Table 4-29: World Multiple Sclerosis Vaccine Market 2011-2021
Table 4-30: World Obesity Vaccine Market 2011-2021
Table 4-31: World PIV-3 Vaccine Market 2011-2021
Table 4-32: World Parkinson’s Disease Vaccine Market 2011-2021
Table 4-33: World Plague Vaccine Market 2011-2021
Table 4-34: World RSV Vaccine Market 2011-2021
Table 4-35: World Ross River Virus Vaccine Market 2011-2021
Table 4-36: World Shigellosis Vaccine Market 2011-2021
Table 4-37: World Stroke Vaccine Market 2011-2021
Table 4-38: World Tuberculosis Vaccine Market 2011-2021
Table 4-39: World West Nile Virus Vaccine Market 2011-2021

Filed in: Pharmaceutical
Tags: 
More Reports
Title Price Buy Now

Ambulatory EHR Market by Delivery Mode (Cloud-based, On-premise), Application (e-Prescribing, PHM, Health Analytics, Practice, Patient & Referral Management), Practice Size (Large, Small-to-Medium, Solo), End User (Independent) – Global Forecast to 2027

“The ambulatory EHR market is projected to grow at a CAGR of 6.1% between 2022 and 2027.” The global ambulatory EHR market is projected to reach USD 5.7 billion in 2022 to USD 7.7 billion by 2027, at a CAGR of 6.1%during the forecast period. Growth in this market is driven by the opportunities provided by the market such as increasing demand for cloud-based ambulatory EHR market, and shift towards patient-centric healthcare delivery. However, the interoperability issues & data security concerns are some of the challenges that are expected to limit the growth of the market to a certain extent during the forecast period. “Cloud-based was the fastest-growing segment in the delivery mode of ambulatory EHR market in 2021” Cloud-based segment is projected to growth at the hi......
 $4950

Pharmaceutical Excipients Market by Product (Organic Chemicals (Carbohydrates), Inorganic Chemicals (Calcium Phosphate)), Functionality (Fillers, Binders, Lubricants, Preservatives), Formulation (Tablets, Capsules, Parenteral) – Global Forecast to 2027

“The pharmaceutical excipients market growth can be attributed to factors such as the rising pharmaceuticals market, advancements in functional excipients, and the growing generics market. The rapidly growing biopharmaceuticals sector will also influence market growth..” The pharmaceutical excipients market is projected to reach USD 11.5 Billion by 2027 from USD 8.6 Billion in 2022, at a CAGR of 5.9% during the forecast period.The growth can be attributed to the expanding pharmaceutical industry which has fueled the drug production thereby increasing consumption rate for excipients. Additionally, factors like functional excipients development and upsurge in generics market is also likely to propel market growth. “The fillers & diluents functionality accounted for the larges......
 $

Digital Pharmacy Market by Drug (Rx, OTC), Product (Medicine, Personal Care, Vitamins & Supplements, Diabetes, CVD, Oncology), Platform (Apps, Websites), Business Model (Captive, Franchise, Aggregator), Geographic (Urban, Rural) – Global Forecasts to 2027

“Digital Pharmacy market to register a CAGR of 17.0%  during the forecasts period The digital pharmacy market is expected to reach USD 211.9 billion by 2027 from USD 96.5 billion in 2022, at a CAGR of 17.0% during the forecast period. The growth of this market is driven by the growing consumer preference toward buying online medicines during and post COVID-19 pandemic, consolidation in the market and partnerships, and increasing geriatric population. However, patients relying on pharmacists for clinical support and increasing number of illegal pharmacies are expected to restrain the growth of this market during the forecast period. “Over-the-counter (OTC) products segment is estimated  to grow at the highest rate during the forecast period” On the basis  ofdrug type, t......
 $4950

Pharmacy Automation Market by Product (Automated Medication Dispensing & Storage Systems, Table-Top Counters, Retrieval Systems, Medication Compounding), End User (Inpatient, Outpatient (Fast-Track Clinics), Retail Pharmacies) – Global Forecast to 2027

The pharmacy automation market is expected to grow at a CAGR of 7.9% in the forecast period. The pharmacy automation market is projected to reach USD 8.2 billion by 2027 from USD 5.6 billion in 2022, at a CAGR of 7.9% during the forecast period. The growth in this market is attributed to the growing need to minimize medication errors, rapid decentralization of pharmacies, and growing focus on automation to reduce labor costs. However, the stringent regulations that delay product launches can inhibit the growth of this market. Based on product, the automated medication dispensing and storage systems segment holds the largest market share in 2021 Based on products, the pharmacy automation market is segmented into automated medication dispensing and storage systems, automated packagi......
 $4950

Topical Drug Delivery Market by Type (Semi-solids (Creams, Gels, Lotions), Solids(Suppositories), Liquids(Solutions), Transdermal products), Route(Dermal, Ophthalmic), Facility of Use (Homecare setting, Hospitals, Burn Centres) – Global Forecast to 2027

The topical drug delivery market is expected to grow at a CAGR of 8.9% in the forecast period. The global topical drug delivery market is projected to reach USD 317.8 billion by 2027 from USD 207.4 billion in 2022, at a CAGR of 8.9%. The growth of this market can largely be attributed to the high prevalence of topical prescription therapy for dry eye diseases,  growing focus of pharmaceutical companies on the R&D of smart transdermal drug delivery systems, increase in prevalence of central nervous disorders,  rising preference for non-invasive drug delivery methods. “The semi-solid formulation segment accounted for the largest share of the topical drug delivery market, based on  product in 2021.” Based on products, the topical drug delivery the market is segmented into ......
 $4950

Cognition and Memory Enhancement Market by Product & Service (Cognition & Memory-enhancing Drugs, Brain-boosting Nutraceuticals, Cognitive Assessment & Training Solutions), Region (North America, Europe, Asia Pacific, ROW) – Global Forecast to 2026

“Increasing incidence and prevalence of neurological disorders is a key factors driving growth in the cognition and memory enhancement market’’ The global cognition and memory enhancement market is projected to reach USD 38.9 billion by 2026 from USD 23.4 billion in 2021, at a CAGR of 10.7% during the forecast period. Elevating prevalence of neurological disorders, such as dementia, epilepsy, Parkinson’s disease, Huntington’s disease, headache disorders, multiple sclerosis, neuroinfections, stroke, and cerebral palsy, have increased significantly over the years. “By product & service segment, the cognition & memory-enhancing drugs segment has registered fastest growth rate during the forecast period” Based on product & service, the cognition and memory en......
 $4950

High Potency APIs/HPAPI Market by Type (Innovative, Generic), Type of Synthesis (Synthetic, Biotech, Biosimilars, mAbs, Vaccines), Manufacturers (Captive, Merchant), Application (Oncology, Hormonal Imbalance, Glaucoma) Region – Global forecast to 2027

The HPAPI market is projected to reach USD 39.6 Billion by 2027 from USD 24.5 billion in 2022, at a CAGR of 10.1% from 2022 to 2027. The market is driven by increasing demand for oncology drugs, growing demand for antibody-drug conjugates and others. “The innovative HPAPIs segment is expected to account for the largest share of the market in 2021” Based on type, the HPAPI market is segmented into innovative and generic. The innovative segment is expected to account for the largest share of the HPAPI market in 2021. The large share can be attributed to the increased R&D investments. “The Synthetic APIs segment to account for the largest share of the market in 2021” Based on type of synthesis, the market is segmented into synthetic and biotech HPAPIs. The synthetic AP......
 $4950

Plasma Fractionation Market by Product (Immunoglobulins, Albumin, Protease Inhibitors, von Willebrand Factor, PCC), Application (Neurology, Immunology, Hematology, Rheumatology), End User (Clinical Research, Hospitals & Clinics) – Global Forecast to 2027

“Increased risk of communicable diseases, Rising prevalence of bleeding disorders in global population, Use of Immunoglobulin’s for a range of neurological conditions, including multiple sclerosis, neuropathic pain, and chronic fatigue syndrome is expected to drive the overall growth of the plasma fractionation market.” The global plasma fractionation market size is projected to reach USD 36.7 billion by 2027 from USD 26.5 billion in 2022, at a CAGR of 6.7% during the forecast period. Market growth is driven mainly by factors such as rapid growth of geriatric population, growing prevalence of respiratory disorders such as alpha-1-antitrypsin deficiency (AATD) and emphysema, and use of plasma fractionation products as first-line therapies for a number of bleeding, hematological, an......
 $4950

Patient Engagement Solutions Market by Component (Software, Services), Delivery (On-Premise, Cloud), Therapy Area (CVD, Diabetes, Obesity, Fitness), Functionality (E-prescribing, Virtual care), End User (Provider, Payer, Patients) – Global Forecast to 2027

“Patient engagement solutions market to register a CAGR of 10.0% from 2022 to 2027” The patient engagement solutions market is projected to reach USD 27.9 billion by 2027 from USD 17.3 billion in 2022, at a CAGR of 10.0% during the forecast period. The growth of this market is driven by the adoption and changes in government regulations to promote patient-centric care and involve patients throughout the care journey, high demand for patient engagement solutions, and the growing utilization of m- health apps. However, interoperability issues for patient engagement solutions and a dreadth of skilled IT professionals in the healthcare industry are expected to restrain the growth of this market during the forecast period. “Services segment is expected to grow at the highest rate......
 $4950

Healthcare Cloud Computing Market by Product (EMR/EHR, VNA, RIS, LIS, PIS), Deployment (Private Cloud, Hybrid Cloud, Public Cloud), Component (Software, Services), Pricing (Spot Pricing), Service (SaaS, IaaS, PaaS), End User – Global Forecasts to 2027

The global Healthcare cloud computing market is projected to reach USD 89.4  billion by 2027 from USD 39.4 billion in 2022, at a CAGR of 17.8%. The factors driving the market are adoption of technologies like telehealth, EHR, big data analytics, IoT, cloud computing, m health, wearlable devices, etc. “The healthcare provider solution was the largest segment in the healthcare cloud computing market in 2021.” The healthcare provider segment accounted for the larger share of 79.2% of the healthcare cloud computing market in 2021. The growing adoption of various health IT solutions such as EHR, e-prescribing, telehealth, mHealth, and others due to COVID-19 is one of the key factors contributing to the growth of this segment. “Among end users, the healthcare providers segment ac......
 $4950
We use cookies to deliver the best possible experience on our website.
By continuing to use this site, or closing this box, you consent to our use of cookies. To learn more, visit our Privacy Policy